Zai

Zai Lab Announces Upcoming Presentations at September Conferences

Retrieved on: 
Monday, August 26, 2019
Zai

SHANGHAI, China and SAN FRANCISCO, Aug. 26, 2019 (GLOBE NEWSWIRE) -- Zai Lab Limited (Zai Lab or the Company) (NASDAQ: ZLAB), a China and US-based innovative commercial-stage biopharmaceutical company, today announced that members of the senior management team will be presenting at the following upcoming conferences this September.

Key Points: 
  • SHANGHAI, China and SAN FRANCISCO, Aug. 26, 2019 (GLOBE NEWSWIRE) -- Zai Lab Limited (Zai Lab or the Company) (NASDAQ: ZLAB), a China and US-based innovative commercial-stage biopharmaceutical company, today announced that members of the senior management team will be presenting at the following upcoming conferences this September.
  • Details of the conferences are as follows:
    Presenter: Dr. Samantha Du, Founder & Chief Executive Officer, Tao Fu, President & Chief Operating Officer, and Jonathan Wang, Head of Business Development
    J.P. Morgan China Healthcare CEO-CFO Forum, China BioMed Innovation and Investment Conference
    Zai Lab (NASDAQ: ZLAB) is a China and U.S.-based innovative commercial stage biopharmaceutical company focused on bringing transformative medicines for cancer, autoimmune and infectious diseases to patients in China and around the world.
  • Zai Labs experienced team has secured partnerships with leading global biopharma companies, generating a broad pipeline of innovative drug candidates targeting the fast-growing segments of China's pharmaceutical market and addressing unmet medical needs.
  • Zai Lab's vision is to become a fully integrated biopharmaceutical company, discovering, developing, manufacturing and commercializing its partners' and its own products in order to impact human health worldwide.

China National Medical Products Administration Grants Innovative Medical Device Designation for Optune® in China

Retrieved on: 
Monday, August 12, 2019
Biotechnology, Health, Radiology, Pharmaceutical, Oncology, Medical devices, Research, Science, Medicine, Clinical research, Health, National Music Publishers Association, Clinical medicine, Zai, Alternating electric field therapy, Medical device, Adverse event, Tumor Treating Fields, Zai Lab, Novocure

We look forward to working closely with the NMPA as Optune advances through the regulatory process in China.

Key Points: 
  • We look forward to working closely with the NMPA as Optune advances through the regulatory process in China.
  • The Innovative Device Designation allows Zai Labto take advantage of an expedited approval procedure for Optune that offers opportunities for pre-consultation with and input from the NMPA throughout the approval process.
  • We are pleased that together with our partners at Zai Lab we are one step closer to commercializing Optune in China.
  • The most common (10%) adverse events related to Optune treatment alone in patients with GBM were medical device site reaction and headache.

Deciphera Pharmaceuticals, Inc. and Zai Lab Limited Announce an Exclusive License Agreement for Ripretinib in Greater China

Retrieved on: 
Tuesday, June 11, 2019
Health, Biotechnology, Clinical trials, Pharmaceutical, General Health, Zai, Royalty payment

In addition, Zai Lab would pay Deciphera royalties from low to high teens on annual net sales of ripretinib in Greater China.

Key Points: 
  • In addition, Zai Lab would pay Deciphera royalties from low to high teens on annual net sales of ripretinib in Greater China.
  • Zai Lab receives exclusive regional development and commercialization rights for ripretinib in Greater China.
  • We believe Zai Lab is the ideal partner for the development and potential commercialization of ripretinib in Greater China, said Steve Hoerter, President and Chief Executive Officer of Deciphera.
  • We are very pleased to enter into this exclusive agreement for ripretinib and look forward to partnering with Deciphera to potentially bring ripretinib to GIST patients in Greater China, said Dr. Samantha Du, Chairman and Chief Executive Officer of Zai Lab.